{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:39:42Z","timestamp":1792337982845,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s13760-019-01143-1","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T10:02:23Z","timestamp":1555668143000},"page":"257-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled clinical trials"],"prefix":"10.1007","volume":"119","author":[{"given":"Adithya","family":"Varma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8567-3092","authenticated-orcid":false,"given":"Panagiotis","family":"Zis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"issue":"7","key":"1143_CR1","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/PSY.0b013e3182294a50","volume":"73","author":"L Colloca","year":"2011","unstructured":"Colloca L, Miller FG (2011) The nocebo effect and its relevance for clinical practice. Psychosom Med 73(7):598\u2013603","journal-title":"Psychosom Med"},{"issue":"5","key":"1143_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1468-1331.2011.03528.x","volume":"19","author":"DD Mitsikostas","year":"2012","unstructured":"Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP (2012) Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 19(5):672\u2013680","journal-title":"Eur J Neurol"},{"issue":"2","key":"1143_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuroscience.2007.02.020","volume":"147","author":"F Benedetti","year":"2007","unstructured":"Benedetti F, Lanotte M, Lopiano L, Colloca L (2007) When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 147(2):260\u2013271","journal-title":"Neuroscience"},{"issue":"11","key":"1143_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/nm.2229","volume":"16","author":"I Tracey","year":"2010","unstructured":"Tracey I (2010) Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med 16(11):1277\u20131283","journal-title":"Nat Med"},{"issue":"2","key":"1143_CR5","first-page":"E157","volume":"14","author":"L Manchikanti","year":"2011","unstructured":"Manchikanti L, Giordano J, Fellows B, Hirsch JA (2011) Placebo and nocebo in interventional pain management: a friend or a foe\u2013or simply foes? Pain Physician 14(2):E157\u2013E175","journal-title":"Pain Physician"},{"key":"1143_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-662-44519-8_6","volume":"225","author":"S Elsenbruch","year":"2014","unstructured":"Elsenbruch S (2014) How positive and negative expectations shape the experience of visceral pain. Handb Exp Pharmacol 225:97\u2013119","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"1143_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.287.5.622","volume":"287","author":"AJ Barsky","year":"2002","unstructured":"Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287(5):622\u2013627","journal-title":"JAMA"},{"issue":"2","key":"1143_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.neuron.2008.06.030","volume":"59","author":"P Enck","year":"2008","unstructured":"Enck P, Benedetti F, Schedlowski M (2008) New insights into the placebo and nocebo responses. Neuron 59(2):195\u2013206","journal-title":"Neuron"},{"issue":"1\u20132","key":"1143_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jns.2015.05.029","volume":"355","author":"P Zis","year":"2015","unstructured":"Zis P, Mitsikostas DD (2015) Nocebo in Alzheimer\u2019s disease; meta-analysis of placebo-controlled clinical trials. J Neurol Sci 355(1\u20132):94\u2013100","journal-title":"J Neurol Sci"},{"issue":"3","key":"1143_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/ene.12014","volume":"20","author":"P Stathis","year":"2013","unstructured":"Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD (2013) Nocebo as a potential confounding factor in clinical trials for Parkinson\u2019s disease treatment: a meta-analysis. Eur J Neurol 20(3):527\u2013533","journal-title":"Eur J Neurol"},{"issue":"7","key":"1143_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/1352458510370793","volume":"16","author":"D Papadopoulos","year":"2010","unstructured":"Papadopoulos D, Mitsikostas DD (2010) Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler (Houndmills, Basingstoke, England). 16(7):816\u2013828","journal-title":"Mult Scler (Houndmills, Basingstoke, England)."},{"issue":"7\u20138","key":"1143_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/21678421.2017.1335325","volume":"18","author":"F Shafiq","year":"2017","unstructured":"Shafiq F, Mitsikostas DD, Zis P (2017) Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 18(7\u20138):576\u2013582","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5","key":"1143_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/0333102410391485","volume":"31","author":"DD Mitsikostas","year":"2011","unstructured":"Mitsikostas DD, Mantonakis LI, Chalarakis NG (2011) Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 31(5):550\u2013561","journal-title":"Cephalalgia"},{"issue":"2","key":"1143_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11910-011-0245-4","volume":"12","author":"DD Mitsikostas","year":"2012","unstructured":"Mitsikostas DD (2012) Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep 12(2):132\u2013137","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"1143_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/AJP.0b013e3182321ad8","volume":"28","author":"W Hauser","year":"2012","unstructured":"Hauser W, Bartram C, Bartram-Wunn E, Tolle T (2012) Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clin J Pain 28(5):437\u2013451","journal-title":"Clin J Pain"},{"issue":"3","key":"1143_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00415-011-6197-4","volume":"259","author":"D Papadopoulos","year":"2012","unstructured":"Papadopoulos D, Mitsikostas DD (2012) A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol 259(3):436\u2013447","journal-title":"J Neurol"},{"issue":"23","key":"1143_CR17","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1212\/WNL.0000000000004004","volume":"88","author":"MA Silva","year":"2017","unstructured":"Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D et al (2017) Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology 88(23):2216\u20132224","journal-title":"Neurology"},{"issue":"1","key":"1143_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.psychres.2013.10.019","volume":"215","author":"DD Mitsikostas","year":"2014","unstructured":"Mitsikostas DD, Mantonakis L, Chalarakis N (2014) Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res 215(1):82\u201386","journal-title":"Psychiatry Res"},{"issue":"10","key":"1143_CR19","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.4088\/JCP.13m08797","volume":"75","author":"BR Rutherford","year":"2014","unstructured":"Rutherford BR, Wall MM, Glass A, Stewart JW (2014) The role of patient expectancy in placebo and nocebo effects in antidepressant trials. J Clin Psychiatry 75(10):1040\u20131046","journal-title":"J Clin Psychiatry"},{"key":"1143_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.seizure.2016.12.003","volume":"45","author":"P Zis","year":"2017","unstructured":"Zis P, Shafiq F, Mitsikostas DD (2017) Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: systematic review and meta-analysis of placebo-controlled clinical trials. Seizure 45:95\u201399","journal-title":"Seizure"},{"issue":"9","key":"1143_CR21","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/MAO.0000000000001555","volume":"38","author":"PA Dimitriadis","year":"2017","unstructured":"Dimitriadis PA, Zis P (2017) Nocebo effect in Meniere\u2019s disease: a meta-analysis of placebo-controlled randomized controlled trials. Otol Neurotol 38(9):1370\u20131375","journal-title":"Otol Neurotol"},{"key":"1143_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jns.2018.03.009","volume":"388","author":"P Zis","year":"2018","unstructured":"Zis P, Hadjivassiliou M, Sarrigiannis PG, Jenkins TM, Mitsikostas DD (2018) Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. J Neurol Sci 388:79\u201383","journal-title":"J Neurol Sci"},{"issue":"7","key":"1143_CR23","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"issue":"1","key":"1143_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"12","key":"1143_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986","journal-title":"Lancet Neurol"},{"issue":"9","key":"1143_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","volume":"10","author":"L Zhou","year":"2017","unstructured":"Zhou L, Liu W, Li W, Li H, Zhang X, Shang H et al (2017) Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Ther Adv Neurol Disord 10(9):315\u2013325","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"1143_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","volume":"87","author":"M Pasnoor","year":"2016","unstructured":"Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V et al (2016) A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology 87(1):57\u201364","journal-title":"Neurology"},{"issue":"2","key":"1143_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s13311-015-0345-y","volume":"12","author":"DB Sanders","year":"2015","unstructured":"Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI (2015) A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis. Neurotherapeutics 12(2):455\u2013460","journal-title":"Neurotherapeutics"},{"issue":"9","key":"1143_CR29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M (2011) Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 82(9):970\u2013977","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1143_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH et al (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71(6):400\u2013406","journal-title":"Neurology"},{"issue":"46","key":"1143_CR31","doi-asserted-by":"publisher","first-page":"12014","DOI":"10.1523\/JNEUROSCI.2947-06.2006","volume":"26","author":"F Benedetti","year":"2006","unstructured":"Benedetti F, Amanzio M, Vighetti S, Asteggiano G (2006) The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 26(46):12014\u201312022","journal-title":"J Neurosci"},{"issue":"2","key":"1143_CR32","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1002\/prp2.208","volume":"4","author":"S Planes","year":"2016","unstructured":"Planes S, Villier C, Mallaret M (2016) The nocebo effect of drugs. Pharmacol Res Perspect 4(2):e00208","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"1143_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12916-019-1272-2","volume":"17","author":"P Zis","year":"2019","unstructured":"Zis P, Sykioti P (2019) Adverse events and nocebo phenomena: treatment or disease specific? BMC Med 17(1):30","journal-title":"BMC Med"},{"key":"1143_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/ner.12946","author":"P Zis","year":"2019","unstructured":"Zis P, Shafique F, Hadjivassiliou M, Blackburn D, Venneri A, Iliodromiti S, Mitsikostas DD, Sarrigiannis PG (2019) Safety, tolerability, and nocebo phenomena during transcranial magnetic stimulation: a systematic review and meta-analysis of placebo-controlled clinical trials. Neuromodulation. \n                    https:\/\/doi.org\/10.1111\/ner.12946\n                    \n                  \n                           (Epub ahead of print)","journal-title":"Neuromodulation"},{"key":"1143_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/bs.irn.2018.07.025","volume":"139","author":"P Zis","year":"2018","unstructured":"Zis P, Mitsikostas DD (2018) Nocebo responses in brain diseases: a systematic review of the current literature. Int Rev Neurobiol 139:443\u2013462","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"1143_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/0019-5413.30519","volume":"41","author":"BA Petrisor","year":"2007","unstructured":"Petrisor BA, Bhandari M (2007) The hierarchy of evidence: levels and grades of recommendation. Indian J Orthop 41(1):11\u201315","journal-title":"Indian J Orthop"},{"issue":"3","key":"1143_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15265161.2011.652798","volume":"12","author":"RE Wells","year":"2012","unstructured":"Wells RE, Kaptchuk TJ (2012) To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth 12(3):22\u201329","journal-title":"Am J Bioeth"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01143-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-019-01143-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01143-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T23:24:34Z","timestamp":1587165874000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-019-01143-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1007\/s13760-019-01143-1","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,19]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}